The Manufacturers Life Insurance Company Grows Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

The Manufacturers Life Insurance Company lifted its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 14.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 553,163 shares of the company’s stock after buying an additional 69,712 shares during the period. The Manufacturers Life Insurance Company owned about 0.22% of Lyell Immunopharma worth $802,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Susquehanna Fundamental Investments LLC bought a new stake in shares of Lyell Immunopharma in the 1st quarter worth approximately $191,000. Acadian Asset Management LLC purchased a new position in Lyell Immunopharma in the 1st quarter worth approximately $173,000. TD Asset Management Inc lifted its position in Lyell Immunopharma by 4.2% in the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after purchasing an additional 40,800 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lyell Immunopharma during the first quarter valued at approximately $64,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Lyell Immunopharma by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock worth $974,000 after purchasing an additional 38,487 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LYEL has been the subject of several recent analyst reports. Bank of America lowered their price objective on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, June 27th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research report on Monday, August 19th.

Lyell Immunopharma Price Performance

LYEL stock opened at $1.18 on Monday. The firm has a 50-day moving average of $1.35 and a 200 day moving average of $1.88. The company has a market cap of $300.83 million, a P/E ratio of -1.31 and a beta of -0.53. Lyell Immunopharma, Inc. has a 1 year low of $1.06 and a 1 year high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The company had revenue of $0.01 million for the quarter. On average, equities research analysts expect that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.